RED BANK, NJ / ACCESSWIRE / July 14, 2015 / Management of Genesis Electronics Group, Inc. (OTC Pink: GEGI) announced today that they have received notice from the Bureau of the Land Management (BLM) that is has completed its financial requirements as per it sublease mining agreement for the 20 acre claim on the property known as “Mav5-E” (Located in the Osceola Mining District in Nevada, White Pine County). 

The Bureau of Land Management (BLM) is an agency within the United States Department of the Interior that administers more than 247.3 million acres of public lands in the United States which constitutes one-eighth of the landmass of the country. President Harry S. Truman created the BLM in 1946 by combining two existing agencies; the General Land Office and the Grazing Service. The agency manages the federal government’s nearly 700 million acres of subsurface mineral estate located beneath federal, state and private lands severed from their surface rights by the Homestead Act of 1862. 

Mr. Raymond F. Purdon, President & CEO, commented, “The completion of this bond allows us commence activity on our lease. We have been preparing for this over the last few months and expect to be initiating mining operations shortly. This is a very exciting time for Genesis as we move into this phase of our corporate strategy. We have been working on our business plan for the last year and are pleased to be in position to begin to realize the benefits of our efforts.”

About Genesis Electronics Group, Inc.

Genesis Electronics Group, Inc. is a holding company which makes acquisitions, investments, and enters into strategic business partnerships. The Company works with organizations that are looking for capital, management assistance, or help in reaching their target markets to realize their true potential. In May 2008, Genesis completed a merger with Genesis Electronics, Inc. a company that is engaged in the development of solar and alternative energy applications for consumer devices such as mobile phones device. In March of the this year the Company finalized the lease and mining agreement for a 20 acre claim on the property known as “Mav5-E”. Located in the Osceola Mining District in Nevada, White Pine County, approximately 29 miles southeast of Ely, the project consists of 985 acres is divided up in thirteen claims. The Company operates the mine through its wholly owned subsidiary, Genesis Mining Corp: www.genesisminingcorp.com and www.genesiselectronicsgroup.com.

Safe Harbor Statement

Certain statements in this press release that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “future,” “may,” “will,” “would,” “should,” “plan,” “projected,” “intend,” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements ofGenesis to be materially different from those expressed or implied by such forward-looking statements. Genesis’s future operating results are dependent upon many factors, including but not limited to the Company’s ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company’s control; and (iv) other risk factors.

For more information contact:

Raymond F. Purdon
Tel: (732) 936-8690
Email: info@gennesiselectronicsgroup.com

SOURCE: Genesis Electronics Group, Inc.

ReleaseID: 430555

NEWARK, NJ / ACCESSWIRE / July 14, 2015 / Beneficial Holdings Inc. (PINKSHEETS: BFHJ), today announced that it completed a substantial acquisition for its Energy Solutions subsidiary, BFHJ Energy Solutions LLC, and named Corey Wolff as president of the newly-expanded subsidiary.

Wolff is the founder of Energy Solutions and Installations, Inc. (ESI) and led its growth into one of the top energy management and commercial scale solar installation companies in the US. Certain of the assets of ESI were acquired by the Company for cash under an asset purchase agreement. ESI, a private company, recorded $15.8 million of revenues in 2014 (unaudited).

The Company’s Chairman, President and CEO, Gregory N. Senkevitch stated, “Corey Wolff brings a team of energy management professionals and substantial revenue prospects to our company. Corey grew ESI from a start-up seven years ago into one of the top 50 commercial solar contractors in the United States per Solar Power World magazine.”

The Company’s wholly-owned subsidiary, BFHJ Energy Solutions, LLC (BES), will be located in Jonestown, PA. The Energy Solutions team will begin work on the company’s sales pipeline, which includes more than $100 million of commercial solar projects, representing more than five years of revenues at ESI’s historical run rate. Additional information about the business and capabilities of BES can be found at their website: www.beneficialenergy.net.

“Our team is already at work increasing sales of BES,” Wolff said. “We bring a track record of innovation, growth and success in the energy management and commercial scale solar development space. Our experience and industry contacts allow us to hit the ground running. We have also inherited a substantial pipeline of qualified transactions, teaming agreements and intellectual property arrangements acquired by Beneficial’s management over the last year,” he added.

Senkevitch concluded, “Corey Wolff and his team add substantial skills, experience and capabilities to our Company. Equally important to shareholders as the prospect for increased revenues and earnings, we have acquired a management team that has a solid track record in providing comprehensive energy management solutions to commercial, institutional and governmental customers. This team has the ability to implement our soon to be announced energy management platforms and our entry into the LED streetlight network business. By adding Corey to our management and retaining his experienced team and their backlog, we are continuing to create ‘Value from Market Knowledge’.”

ABOUT BENEFICIAL HOLDINGS, INC.; BFHJ ENERGY SOLUTIONS, LLC:

Beneficial Holdings, Inc. is a holding company with operating service-oriented businesses in the real estate, energy management and financial services sectors. The Company is an integrator of technology and solutions for the built environment and seeks to create “Value from Market Knowledge.” For more information on the Company please visit our web site at www.beneficial-holdings.net.

For more information on BES, our energy solutions subsidiary, please visit the web site at www.beneficialenergy.net.

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. As a general matter, forward-looking statements reflect our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business.

These statements may be identified by the use of forward-looking terminology such as “may,” “will,” “expects,” “plans,” “estimates,” “anticipates,” “projects,” “intends,” “believes,” “outlook” and similar expressions.

The forward-looking statements contained in this news release are based upon our historical performance, current plans, estimates, expectations and other factors we believe are appropriate under the circumstances. The inclusion of this forward-looking information is inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy and some of which might not even be anticipated. Future events and actual results, financial and otherwise, may differ materially from the results discussed in the forward-looking statements. Statements regarding the following subjects, among others, may be forward-looking: our business and investment strategy; our projected operating results; estimates relating to our ability to make distributions to our stockholders in the future and economic trends and economic recoveries.

All information in this release is as of July 14, 2015. The Company does not undertake a duty to update forward-looking statements, including its projected operating results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this news release.

CONTACT:

GREG McANDREWS & ASSOCIATES
Gregory A. McAndrews
(310) 804-7037
greg@gregmcandrews.com

SOURCE: Beneficial Holdings Inc.

ReleaseID: 430543

WHITEFISH, MT / ACCESSWIRE / July 14, 2015 / There are a number of reasons investors worldwide love dermatology companies. For starters, support of innovation has been key in gaining a far better understanding of skin conditions and advancing effective, safe therapies capable of becoming standards of care. Of course, Wall Street loves upside potential. At a more granular level, the logic underscoring dermatology as a good investment is quite diverse. As David M. Steinberg, Managing Director Equity Research at Jeffries, puts it, dermatology products have several general attributes: 1) shorter development timelines; 2) lower clinical trial costs; 3) perceived lower regulatory hurdles; 4) high cash pay components for aesthetics; 5) a recent track record of success; and 6) a really active M&A market, which Mr. Steinberg described as a second way for shareholders to win. Oculus Innovative Sciences’ (NASDAQ: OCLS) CFO Bob Miller and CEO Jim Schutz expanded on Steinberg’s view in the company’s June earnings call, adding 7) derm has strong pricing, product margins, and insurance coverage; 8) it is a concentrated call point, meaning companies don’t need an enormous sales force to cover; 9) derm has fast sales ramps; and 10) dermatology has great valuations or multiples on revenue.

Patents and Exclusivity: More Reasons to Love Derm

FDA exclusivity and patents work in a similar fashion, even though they are different in the origination process. The U.S. Food and Drug Administration’s Code of Federal Regulations Title 21 (more specifically Section 314), the section created in the Hatch-Waxman process, affords derm companies a minimum of three years of monopoly-like marketing exclusivity upon FDA drug approvals. The term is lifted to five years if the FDA deems the product meets the definition of a new chemical entity. During this period, no generic or competitor can sell the same active for the same indication. As mentioned in #7 above, with strong pricing, margins and reimbursement, being shielded from competition is sweet spot for a derm product to capture market and establish a brand.

Patents are derived through a very different procedure. They are granted by the U.S. Patent & Trademark Office anywhere along the development lifeline of a drug and can encompass a wide range of claims to protect intellectual property throughout the life of the patent. As such, they can run concurrently with FDA exclusivity, or even before FDA approval, to fend off competition.

The situation changes slightly for dermatological medical devices (which under FDA rules include certain gels and sprays). The primary pro is that FDA approval of a derm medical device can come at a fraction of the clinical development cost of new drugs and years faster. The main con is there is no FDA exclusivity for medical devices, so patents really matter.

Case in point, Oculus Innovative Sciences just announced the issuance of a US patent for the use of hypochlorous acid (HOCl), the main ingredient in Oculus’ Microcyn technology, for the treatment of atopic dermatitis (eczema). The news is important because OCLS now has the benefit of an FDA approved medical device with solid human clinical evidence and a new patent, which could be a winning combination for the company.

Additionally, Oculus received a U.S. Patent (No. 8,834,445) in 2014 for the treatment of peritonitis using HOCl. That patent enabled Oculus to set the stage for the Ruthigen (NASDAQ: RTGN) spinoff and IPO, which was targeting the use of HOCl as a surgical rinse on abdominal surgeries including peritonitis. Patents matter.

The beauty is the way that patents and FDA regulations can be leveraged to keep capital expenditures down and block competition in a huge global market. There are more than 3,000 identified skin conditions and diseases affecting millions of people daily across the planet, creating a growing medical dermatology market that was estimated at just over $24 billion in pharmaceutical sales in 2014. This forecast and others appear in Dermatological Drugs Market Forecast 2014-2024: Future Prospects for Leading Companies, published in April 2014.

Evidence of the Hot Dermatology Market

Jeffries recently crowned Anacor Pharmaceuticals (NASDAQ: ANAC) as one of its top growth stocks to buy, reiterating its buy rating this month and $80 price target. Anacor’s first approved drug is Kerydin, a topical solution indicated for treating onychomycosis of the toenails. Anacor last year partnered with PharmaDerm, the branded dermatology division of Novartis (NYSE: NVS) company Sandoz, for distribution of Kerydin in the United States. From the Anacor pipeline, investors are watching for results from Anacor’s Phase 3 trial of crisaborole, an investigational non-steroidal topical PDE-4 inhibitor, being evaluated in the trial as a treatment for atopic dermatitis. Results could further catalyze shares of ANAC, which at $79 have already risen more than 140 percent in 2015.

The trend towards derm companies has benefited the IPO space as well. Dermira (NASDAQ: DERM) came public last fall, a time when there was some waxing and waning in the biotech sector, yet was able to boost its offering from an original target of $75 million to rake in $125 million. Dermira is partnered with the UCB Pharma S.A. on the TNF blocker Cimzia, which is being studied in three Phase 3 programs (CIMPASI-1, CIMPASI-2 and CIMPACT) for the treatment of moderate-to-severe plaque psoriasis. Following its successfully completed Phase 2b trial, Dermira has its sights set on initiating a Phase 3 trial of the topical anticholinergic product candidate DRM04 for hyperhidrosis – or excessive sweating – by the end of the year. Further, the first patient in a Phase 2b trial of DRM01, a topical sebum inhibitor, for patients with acne vulgaris was dosed in April. Data from this trial is expected in the first half of 2016.

In the global space, Cosmo Pharmaceuticals, an Italian drugmaker listed in Switzerland, intends to bank some profits by lowering its stake in its dermatology unit Cassiopea from 97 percent to about 50 percent with the upcoming IPO of Cassiopea on the SIX Swiss Exchange. Current Cassiopea investors, including German billionaire Dietmar Hopp’s dievini fund, are expected to gobble up a portion of the shares divested by Cosmo. Cosmo CFO Christoph Tanner says Cassiopea, whose lead product is a steroidal ester androgen antagonist called Winlevi for acne, will go to market for at least 100 million francs (US$107 million). Cassiopea is a company currently with only three employees and a few skin drugs in mid-stage trials. Valeant Pharmaceuticals (NYSE: VRX) has first refusal on Winlevi should Cassiopea outlicense the drug.

Shares of Oculus Innovative Sciences, the aforementioned specialty pharma with a family of derm products built on its Microcyn technology, have been on the upswing since bottoming in May, energized by a better-than-expected quarter and FDA clearance for its novel Alevicyn SG Antipruritic Spray Gel. The product launch is getting underway this month in the U.S. for both prescription and over-the-counter indications as a treatment for a variety of dermatoses, including radiation and atopic dermatitis. Atopic dermatitis is a particularly attractive market. According to the National Eczema Association, the itchy chronic rash affects about 18 million Americans, including around 11 percent of infants and children.

The new Alevicyn product joins a clutch of products in Oculus’ portfolio of marketed therapeutics spanning wound management, skin care, scar management and other derm applications. The company, which is much smaller than most peers with its ~$24 million market capitalization, also has characteristics often seen only in larger firms, such as an animal healthcare division full of new products being sold by a freshly restructured sales model and new marketing channels.

Oculus has eleven interesting medical device approvals in a hot dermatology space with a veteran sales force, solid human clinical evidence and now, an issued patent to create blued sky exclusivity, indicating that things may get really interesting for the company. Simply put, patent exclusivity plus effective derm medical devices without all the costs of new drug applications equate to a compelling future in a large and growing market.

Click here to receive future email updates on Oculus Innovative Sciences developments: http://www.tdmfinancial.com/emailassets/ocls/ocls_landing.php.

Disclaimer:

Except for the historical
information presented herein, matters discussed in this release contain
forward-looking statements that are subject to certain risks and
uncertainties that could cause actual results to differ materially from
any future results, performance or achievements expressed or implied by
such statements. Emerging Growth LLC is not registered with any
financial or securities regulatory authority, and does not provide nor
claims to provide investment advice or recommendations to readers of
this release. Emerging Growth LLC may from time to time have a position
in the securities mentioned herein and may increase or decrease such
positions without notice. For making specific investment decisions,
readers should seek their own advice. Emerging Growth LLC may be
compensated for its services in the form of cash-based compensation or
equity securities in the companies it writes about, or a combination of
the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.

SOURCE: Emerging Growth LLC

ReleaseID: 430554

CONYERS, GA / ACCESSWIRE / July 14, 2015 / GeckoSystems Intl. Corp. (http://www.geckosystems.com/) (OTC Pink: GOSY) (PINKSHEETS: GOSY), announced today that the company has reached mutually acceptable licensing terms with Fubright Communications Co. Ltd. for use of their GeckoNav(tm) self-guidance mobile robot software on SoftBank Robotics’ personal robots to all Pepper users in Japan. Fubright is the recent winner of SoftBank’s Pepper robot software contest over several dozen other entrants with their Ninnin app for elderly dementia care.

“The now agreed upon licensing schedule sets the royalty stream to GeckoSystems. It is nearly an order magnitude greater than what Microsoft receives from OEM’s per PC. It differs in that it is on an annual, per year basis to fit SoftBank’s pricing strategy in Japan,” stated Martin Spencer, CEO, GeckoSystems.

As a long time Japanese agent of GeckoSystems, Mr. Katsuji Fujii is credited with these successful negotiations with Fubright.

Fubright won SoftBank’s Pepper robot software contest against several dozens of competitors late last year with an app known as Ninnin Pepper. Ninnin allows the Pepper robot to assist in waking up dementia patients and take their scheduled medicines on time. Pepper also reports to a doctor via Internet if the patient did not consume their pills. On a daily basis, the robot communicates with the patient by asking about their family to stimulate memory and the touch screen tablet on its chest has the capability to send and receive pictures and messages from a family member. (“Japanese humanoid robot called Pepper gets its own app”)

Recently, Fubright witnessed a live demonstration in Japan of GeckoNav and received training from another Japanese partner of GeckoSystems, iXs Research, in its operation. GeckoNav is portable and very little R&D will be required to migrate and integrate the Company’s flagship real time sense and avoid self-driving artificial intelligence (AI) software to the Pepper robot that enables errand running, etc. with a “loose crowd” level of autonomy.

No other AI mobile robot company in Asia, the US, or Europe is known to have mobile robot solutions with this level of automatic self-guidance with dynamic obstacle avoidance movement that is “jet fighter pilot” capable in complex, fluid environments. Those that suggest they do have this capability require tens of thousands of dollars of computer and sensory systems hardware to achieve what the Company does for a few hundred. GeckoSystems was founded over 15 years ago and over $8,000,000 has been spent to develop their low cost, breakthrough, proprietary AI technology. The company developed their SafePath(tm) AI mobile robot navigation technologies to address those very important linchpin requirements for any mobile robot to be truly utilitarian (convenient like a home appliance), while being cost effective for a compelling value proposition.

Perhaps most noteworthy is SoftBank’s Pepper robot critical need for more application software to improve its value proposition, as discussed here: “Pepper is Getting Ready”.

“When we talk about the profitability of domestic robots, however, experience tells us that, at the moment, the robots which are profitable are not those which ‘can do a lot of different things’ but those which do one thing and do it well. With the SoftBank business model Pepper can be bought for a more reasonable price than a domestic humanoid robot has ever had, but for Pepper to find its place in the home it will have to show that it is different and will have to demonstrate how its unique ability to recognize emotions from human gestures and tones of voice will be usefully applied in the domestic sphere.”

SoftBank is encouraging and seeking apps for their Pepper robot just as they seek apps for the smart phones they sell in Japan, and as Apple does for its smart phones. GeckoSystems alliance with Fubright enables greater credibility, and acceptance by Japanese users for GeckoSystems and consequently enhances sales growth and licensing revenues.

Presently the Pepper robot lacks the fundamental and necessary functionality to safely run errands and automatically follow the care receiver. Again, real time sense and avoid moving of unmapped obstacles is a functional deficiency that precludes the Pepper from fully exploiting Fubright’s win of SoftBank’s Pepper software contest with their “Ninnin Pepper” for aiding those challenged by dementia. This need coupled with the robustness, maturity and ease of migration of GeckoNav to the Pepper is why Fubright is partnering with GeckoSystems.

SoftBank is fully aware of the reality that the Japanese heath care insurance system decreed over a year ago that their insurance program would pay 90% of the monthly costs of providing personal mobile robots for eldercare. SoftBank has a billion dollar market opportunity to sell millions of Pepper robots in the next few years. Foxconn wishes to manufacture those millions of Pepper robots for the Japanese and Chinese markets. Alibaba wishes to distribute a Chinese version of the Pepper in China.

On June 20, SoftBank sold a month’s production of Peppers, (1,000 robots) in the first few minutes of being offered online. “SoftBank sells 1,000 units of its Pepper robot in first minute of online trade” Per their July 3 press release: “SoftBank to Offer 1,000 ‘Pepper’ Units on July 31”.

Fubright and GeckoSystems want to have their proprietary AI software on every Pepper sold in the world.

“Due to Fubright’s preeminent position and relationship with SoftBank Robotics, it is very satisfying to make this announcement and present this analysis to all our stockholders, both present and future. As would be expected at this time, we have other ongoing negotiations. After many years of patience by our current 1300+ stockholders, they can be assured that the present management continues to work to maximize their investments in GeckoSystems whether by organic growth or being acquired at a rewarding premium,” concluded Spencer. 

Recent third party market research:

Service Robotics Market (Professional and Personal), by Application (Defense, Agriculture, Medical, Domestic & Entertainment), & by Geography – Analysis Forecast (2014 – 2020)

Robotic systems are looked at as the future assistants that are designed to help people to do what they want to do in a natural and spontaneous manner. Moreover, with the emergence of ubiquitous computing and communication environments, robots will be able to call upon an unlimited knowledge base and coordinate their activities with other devices and systems. Additionally, the growing spread of ubiquitous computing will lead to robot technologies being embedded into ubiquitous ICT networks to become human agents of physical actions, enhancing and extending the physical capabilities and senses.

The report focuses on giving a detailed view of the complete service robotics industry with regards to the professional and personal applications as well as the geography market. Apart from the market segmentation, the report also includes the critical market data and qualitative information for each product type along with the qualitative analysis; such as Porter’s five force analysis, market time-line analysis, industry breakdown analysis, and value chain analysis. The global service robotics market is estimated to reach up to $19.41 billion by 2020 growing at a CAGR of 21.5% from 2014 to 2020.

Global Service Robot Market 2014-2018: Key Vendors are GeckoSystem, Honda Motor, iRobot and Toyota Motor

Worldwide Service Robot Market 2018 Analysis & Forecasts Report

The report recognizes the following companies as the key players in the Global Service Robot Market: GeckoSystem Intl. Corp., Honda Motor Co. Ltd., iRobot Corp. and Toyota Motor Corp.

From Forbes:

Investors Take Note, The Next Big Thing Will Be Robots

BusinessInsider makes some key points:

– The multibillion-dollar global market for robotics, long dominated by industrial and logistics uses, has begun to see a shift toward new consumer and office applications. There will be a $1.5 billion market for consumer and business robots by 2019.

– The market for consumer and office robots will grow at a CAGR of 17% between 2014 and 2019, seven times faster than the market for manufacturing robots.

Note: BusinessInsider.com’s forecasts do not include pent up demand for family care social robots anywhere in the world.

About GeckoSystems:

GeckoSystems has been developing innovative robotic technologies for over fifteen years. It is CEO Martin Spencer’s dream to make people’s lives better through robotic technology.

An overview of GeckoSystems’ progress containing over 700 pictures and 120 videos can be found at http://www.geckosystems.com/timeline/.

These videos illustrate the development of the technology that makes GeckoSystems a world leader in Service Robotics development. Early CareBot prototypes were slower and frequently pivoted in order to avoid a static or dynamic obstacle; later prototypes avoided obstacles without pivoting. Current CareBots avoid obstacles with a graceful “bicycle smooth” motion. The latest videos also depict the CareBot’s ability to automatically go faster or slower depending on the amount of clutter (number of obstacles) within its field of view. This is especially important when avoiding moving obstacles in “loose crowd” situations like a mall or an exhibit area.

In addition to the timeline videos, GeckoSystems has numerous YouTube videos. The most popular of which are the ones showing room-to-room automatic self-navigation of the CareBot through narrow doorways and a hallway of an old 1954 home. You will see the CareBot slow down when going through the doorways because of their narrow width and then speed up as it goes across the relatively open kitchen area. There are also videos of the SafePath(tm) wheelchair, which is a migration of the CareBot AI centric navigation system to a standard power wheelchair, and recently developed cost effective depth cameras were used in this recent configuration. SafePath navigation is now available to OEM licensees and these videos show the versatility of GeckoSystems’ fully autonomous navigation solution. 

GeckoSystems, Star Wars Technology

The company has successfully completed an Alpha trial of its CareBot personal assistance robot for the elderly. It was tested in a home care setting and received enthusiastic support from both caregivers and care receivers. The company believes that the CareBot will increase the safety and well being of its elderly charges while decreasing stress on the caregiver and the family.

CareBot has incorporated Microsoft Kinect depth cameras that result in a significant cost reduction.

Kinect Enabled Personal Robot video

Above, the CareBot demonstrates static and dynamic obstacle avoidance as it backs in and out of a narrow and cluttered alley. There is no joystick control or programmed path; movements are smoother that those achieved using a joystick control. GeckoNav creates three low levels of obstacle avoidance: reactive, proactive, and contemplative. Subsumptive AI behavior within GeckoNav enables the CareBot to reach its target destination after engaging in obstacle avoidance.

More information on the CareBot personal assistance robot:

http://www.geckosystems.com/markets/CareBot.php

GeckoSystems stock is quoted in the U.S. over-the-counter (OTC) markets under the ticker symbol GOSY.

http://www.otcmarkets.com/stock/GOSY/quote

Here is a stock message board devoted to GOSY recommended by us:

http://investorshangout.com/board/62282/Geckosystems+Intl+Co-GOSY

GeckoSystems uses LinkedIn and Twitter as its primary social media site for investor updates.

Spencer’s LinkedIn.com profile

Spencer tweets as @GrandpaRobot

Safe Harbor:

Statements regarding financial matters in this press release other than historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such statements about the Company’s future expectations, including future revenues and earnings, technology efficacy and all other forward-looking statements be subject to the Safe Harbors created thereby. The Company is a development stage firm that continues to be dependent upon outside capital to sustain its existence. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results.

CONTACT:

GeckoSystems Intl. Corp.
Main number: +1 678-413-9236
Fax: +1 678-413-9247
Website: http://www.geckosystems.com/

SOURCE: GeckoSystems Intl. Corp.

ReleaseID: 430553